Long-term extension, multicenter, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg. 1.5 mg, 2 mg. or 2.5 mg tid) in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH)- CHEST - 2 Study.
This is a Multicenter, multinational, open label, one arm study in patients with CTEPH.
and #149; Treatment Phase:
Titration Phase: 8 weeks
Main-Study Phase: Duration until BAY 63-2521 receives official approval and will be commercially available
and #149; Safety Follow Up Phase: 30 days
BAY 63-2521 will be administered orally as a tablet in doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg t.i.d.
• Patients who have completed 16 weeks of treatment in the double blind trial CHEST-1.
• Patients must have given their written informed consent to participate in the study after having received adequate previous information and prior to any study-specific procedures.